Exagen Inc., a prominent provider of autoimmune testing, has announced its participation in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event will feature a fireside chat with the company’s management, providing insights into their innovative approaches to autoimmune diagnostics. Attendees can access a live and archived webcast of the discussion through Exagen’s Investor Relations website.

For those interested in the health implications of autoimmune diseases, Exagen is focused on improving the diagnosis and management of conditions like lupus, rheumatoid arthritis, and Sjögren’s disease. Their flagship product, AVISE® CTD, is designed to help healthcare providers accurately identify these complex diseases earlier, which can lead to better treatment outcomes. By offering a suite of AVISE-branded tests, Exagen aims to provide clarity in decision-making for patients facing chronic autoimmune challenges.

The company operates a CLIA-certified and CAP-accredited laboratory, ensuring that their testing processes meet high standards for quality and reliability. With a commitment to research and patient-centered care, Exagen is tackling the ongoing challenges associated with autoimmune disease management. Their work is particularly relevant for individuals looking to understand and address the impacts of autoimmune conditions on their health and longevity.

As Exagen continues to innovate in the field of autoimmune diagnostics, their participation in investor conferences highlights the importance of advancing medical technology for better patient outcomes. For more details about their upcoming conference and initiatives, you can visit Exagen’s official site.

Source